Hemoglobinopathies are among the most common inherited diseases around the world. The conditions can be divided into two main groups: thalassemia syndromes and structural hemoglobin variants. α- and β-thalassemia are the main types of thalassemia and the main structural hemoglobin variants are HbS, HbE and HbC.
The global hemoglobinopathy market is estimated to account for US$ 523.4 Mn in terms of value in 2019 and is expected to reach US$ 1,001.6 Mn by the end of 2027.
Global Hemoglobinopathy Market: Drivers
Increasing prevalence of thalassemia is expected to boost growth of the global hemoglobinopathy market over the forecast period. For instance, the study, ‘Alpha-Thalassemia in North Morocco: Prevalence and Molecular Spectrum’, published in the journal BioMed Research International, in March 2019, the prevalence of α-thalassemia was 26.59% in newborns.
Global Hemoglobinopathy Market: Opportunities
R&D in the area of hemoglobinopathies is expected to offer lucrative growth opportunities for players in the market. For instance, in February 2019, researchers from The University of British Columbia, and Canada reported assessment of serum non-transferrin bound iron, a toxic biochemical that accumulates in blood when high amount of iron is absorbed, in Cambodian women who received daily iron supplements in accordance with the 2016 global World Health Organization (WHO) guidelines.
Global Hemoglobinopathy Market: Restraints
The accuracy of the most conventional and affordable methods for diagnosing hemoglobinopathy such as RBC count and electrophoresis highly depends on experience and skills of the technician performing the test. The lack of high sensitivity and specificity in terms of most commonly used diagnostic tests can leads to human errors and misinterpretation of results, which may hinder market growth to a certain extent.
Routine Red Blood Cell (RBC) count segment in the global hemoglobinopathy market was valued at US$ 161.4 Mn in 2019 and is expected to reach US$ 277.9 Mn by 2027 at a CAGR of 7.4% during the forecast period. Routine red blood cell count is the standard test performed to find out prognosis of various diseases such as infections, and hemoglobinopathies. This factors is expected to support growth of the segment over the forecast period.
The Sickle Cell Disease segment held dominant position in the global hemoglobinopathy market in 2019, accounting for 52.3% share in terms of value, followed by Beta Thalassemia and Alpha Thalassemia, respectively. According to Center for Disease Control and Prevention, as of 2016, around 100,000 people in the U.S. are affected by sickle cell diseases or SCDs. Sickle cell diseases are very common among black or African Americans. Growing prevalence of the disease will give rise to an increased demand for sickle cell disease prevention and cure, thereby augmenting the growth of the segment over the forecast period.
The diagnostic laboratories segment held dominant position in the global hemoglobinopathy market in 2018, accounting for 49.6% share in terms of value, followed by hospitals and clinics, respectively. Diagnostic laboratories perform initial testing for several diseases including hemoglobinopathies. This factor is expected to support growth of the segment over the forecast period.
Premarital and prenatal genetic testing for the sickle cell trait identification is rapidly gaining popularity in developed as well as developing nations. In the U.S., new-born screening for various hemoglobinopathy disorders is mandatory.
Sickle cell hemoglobinopathy has a worldwide manifestation, although it is more concentrated in some particular regions and ethnic groups. It is thought to have originated as a resistance trait to malaria endemic in areas such as Africa and parts of Asia such as in India. Various studies are being conducted to understand the malaria and hemoglobinopathy correlation to develop better diagnosis and treatment measures.
Global Hemoglobinopathy Market: Competitive Landscape
Major players operating in the global hemoglobinopathy market include, Abbott Diagnostics, AstraZeneca, Bio-Rad Laboratories, Inc., Danaher Corp., ReachBio Research Labs, Mindray Medical International Ltd., Nexcelom Bioscience LLC, Nihon Kohden Europe Ltd., PerkinElmer Inc., Siemens Healthineers, Bluebird Bio Inc., Sysmex Europe GmbH, Celgene Corporation, and Acceleron Pharma Inc.
Global Hemoglobinopathy Market: Key Developments
June 2019: Bluebird Bio Inc. received the European Medicines Agency (EMA) approval for its product, Zynteglo, a gene therapy that contains autologous CD34+ cells encoding βA-T87Q-globin gene, for the treatment of transfusion-dependent β-thalassemia with no β0/β0 genotype
January 2019: Celgene Corporation and Acceleron Pharma Inc. started their clinical trial for luspatercept, a drug for the treatment of adult patients with beta-thalassemia
Joining thousands of companies around the world committed to making the Excellent Business Solutions.